Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 43.23% year-on-year.
Fairly Valued
The company’s latest PE is 51.19, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 96.10M shares, decreasing 1.93% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 2.21M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.50.